Cargando…

Prevalence and extent of infarct and microvascular obstruction following different reperfusion therapies in ST-elevation myocardial infarction

BACKGROUND: Microvascular obstruction (MVO) describes suboptimal tissue perfusion despite restoration of infarct-related artery flow. There are scarce data on Infarct Size (IS) and MVO in relation to the mode and timing of reperfusion. We sought to characterise the prevalence and extent of microvasc...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Jamal N, Razvi, Naveed, Nazir, Sheraz A, Singh, Anvesha, Masca, Nicholas GD, Gershlick, Anthony H, Squire, Iain, McCann, Gerry P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4041906/
https://www.ncbi.nlm.nih.gov/pubmed/24884638
http://dx.doi.org/10.1186/1532-429X-16-38
_version_ 1782318734675804160
author Khan, Jamal N
Razvi, Naveed
Nazir, Sheraz A
Singh, Anvesha
Masca, Nicholas GD
Gershlick, Anthony H
Squire, Iain
McCann, Gerry P
author_facet Khan, Jamal N
Razvi, Naveed
Nazir, Sheraz A
Singh, Anvesha
Masca, Nicholas GD
Gershlick, Anthony H
Squire, Iain
McCann, Gerry P
author_sort Khan, Jamal N
collection PubMed
description BACKGROUND: Microvascular obstruction (MVO) describes suboptimal tissue perfusion despite restoration of infarct-related artery flow. There are scarce data on Infarct Size (IS) and MVO in relation to the mode and timing of reperfusion. We sought to characterise the prevalence and extent of microvascular injury and IS using Cardiovascular magnetic resonance (CMR), in relation to the mode of reperfusion following acute ST-Elevation Myocardial Infarction (STEMI). METHODS: CMR infarct characteristics were measured in 94 STEMI patients (age 61.0 ± 13.1 years) at 1.5 T. Seventy-three received reperfusion therapy: primary percutaneous coronary-intervention (PPCI, n = 47); thrombolysis (n = 12); rescue PCI (R-PCI, n = 8), late PCI (n = 6). Twenty-one patients presented late (>12 hours) and did not receive reperfusion therapy. RESULTS: IS was smaller in PPCI (19.8 ± 13.2% of LV mass) and thrombolysis (15.2 ± 10.1%) groups compared to patients in the late PCI (40.0 ± 15.6%) and R-PCI (34.2 ± 18.9%) groups, p <0.001. The prevalence of MVO was similar across all groups and was seen at least as frequently in the non-reperfused group (15/21, [76%] v 33/59, [56%], p = 0.21) and to a similar magnitude (1.3 (0.0-2.8) v 0.4 [0.0-2.9]% LV mass, p = 0.36) compared to patients receiving early reperfusion therapy. In the 73 reperfused patients, time to reperfusion, ischaemia area at risk and TIMI grade post-PCI were the strongest independent predictors of IS and MVO. CONCLUSIONS: In patients with acute STEMI, CMR-measured MVO is not exclusive to reperfusion therapy and is primarily related to ischaemic time. This finding has important implications for clinical trials that use CMR to assess the efficacy of therapies to reduce reperfusion injury in STEMI.
format Online
Article
Text
id pubmed-4041906
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40419062014-06-04 Prevalence and extent of infarct and microvascular obstruction following different reperfusion therapies in ST-elevation myocardial infarction Khan, Jamal N Razvi, Naveed Nazir, Sheraz A Singh, Anvesha Masca, Nicholas GD Gershlick, Anthony H Squire, Iain McCann, Gerry P J Cardiovasc Magn Reson Research BACKGROUND: Microvascular obstruction (MVO) describes suboptimal tissue perfusion despite restoration of infarct-related artery flow. There are scarce data on Infarct Size (IS) and MVO in relation to the mode and timing of reperfusion. We sought to characterise the prevalence and extent of microvascular injury and IS using Cardiovascular magnetic resonance (CMR), in relation to the mode of reperfusion following acute ST-Elevation Myocardial Infarction (STEMI). METHODS: CMR infarct characteristics were measured in 94 STEMI patients (age 61.0 ± 13.1 years) at 1.5 T. Seventy-three received reperfusion therapy: primary percutaneous coronary-intervention (PPCI, n = 47); thrombolysis (n = 12); rescue PCI (R-PCI, n = 8), late PCI (n = 6). Twenty-one patients presented late (>12 hours) and did not receive reperfusion therapy. RESULTS: IS was smaller in PPCI (19.8 ± 13.2% of LV mass) and thrombolysis (15.2 ± 10.1%) groups compared to patients in the late PCI (40.0 ± 15.6%) and R-PCI (34.2 ± 18.9%) groups, p <0.001. The prevalence of MVO was similar across all groups and was seen at least as frequently in the non-reperfused group (15/21, [76%] v 33/59, [56%], p = 0.21) and to a similar magnitude (1.3 (0.0-2.8) v 0.4 [0.0-2.9]% LV mass, p = 0.36) compared to patients receiving early reperfusion therapy. In the 73 reperfused patients, time to reperfusion, ischaemia area at risk and TIMI grade post-PCI were the strongest independent predictors of IS and MVO. CONCLUSIONS: In patients with acute STEMI, CMR-measured MVO is not exclusive to reperfusion therapy and is primarily related to ischaemic time. This finding has important implications for clinical trials that use CMR to assess the efficacy of therapies to reduce reperfusion injury in STEMI. BioMed Central 2014-05-27 /pmc/articles/PMC4041906/ /pubmed/24884638 http://dx.doi.org/10.1186/1532-429X-16-38 Text en Copyright © 2014 Khan et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Khan, Jamal N
Razvi, Naveed
Nazir, Sheraz A
Singh, Anvesha
Masca, Nicholas GD
Gershlick, Anthony H
Squire, Iain
McCann, Gerry P
Prevalence and extent of infarct and microvascular obstruction following different reperfusion therapies in ST-elevation myocardial infarction
title Prevalence and extent of infarct and microvascular obstruction following different reperfusion therapies in ST-elevation myocardial infarction
title_full Prevalence and extent of infarct and microvascular obstruction following different reperfusion therapies in ST-elevation myocardial infarction
title_fullStr Prevalence and extent of infarct and microvascular obstruction following different reperfusion therapies in ST-elevation myocardial infarction
title_full_unstemmed Prevalence and extent of infarct and microvascular obstruction following different reperfusion therapies in ST-elevation myocardial infarction
title_short Prevalence and extent of infarct and microvascular obstruction following different reperfusion therapies in ST-elevation myocardial infarction
title_sort prevalence and extent of infarct and microvascular obstruction following different reperfusion therapies in st-elevation myocardial infarction
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4041906/
https://www.ncbi.nlm.nih.gov/pubmed/24884638
http://dx.doi.org/10.1186/1532-429X-16-38
work_keys_str_mv AT khanjamaln prevalenceandextentofinfarctandmicrovascularobstructionfollowingdifferentreperfusiontherapiesinstelevationmyocardialinfarction
AT razvinaveed prevalenceandextentofinfarctandmicrovascularobstructionfollowingdifferentreperfusiontherapiesinstelevationmyocardialinfarction
AT nazirsheraza prevalenceandextentofinfarctandmicrovascularobstructionfollowingdifferentreperfusiontherapiesinstelevationmyocardialinfarction
AT singhanvesha prevalenceandextentofinfarctandmicrovascularobstructionfollowingdifferentreperfusiontherapiesinstelevationmyocardialinfarction
AT mascanicholasgd prevalenceandextentofinfarctandmicrovascularobstructionfollowingdifferentreperfusiontherapiesinstelevationmyocardialinfarction
AT gershlickanthonyh prevalenceandextentofinfarctandmicrovascularobstructionfollowingdifferentreperfusiontherapiesinstelevationmyocardialinfarction
AT squireiain prevalenceandextentofinfarctandmicrovascularobstructionfollowingdifferentreperfusiontherapiesinstelevationmyocardialinfarction
AT mccanngerryp prevalenceandextentofinfarctandmicrovascularobstructionfollowingdifferentreperfusiontherapiesinstelevationmyocardialinfarction